| A review of a novel, Bruton’s tyrosine kinase inhibitor, ibrutinib CS Lee, MA Rattu, SS Kim Journal of Oncology Pharmacy Practice 22 (1), 92-104, 2016 | 70 | 2016 |
| An overview of the changing landscape of treatment for advanced melanoma CS Lee, CM Thomas, KE Ng Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 37 (3 …, 2017 | 41 | 2017 |
| Pretreatment nutritional status and response to checkpoint inhibitors in lung cancer CS Lee, CE Devoe, X Zhu, JS Fishbein, N Seetharamu Lung cancer management 9 (2), LMT31, 2020 | 24 | 2020 |
| Osimertinib in EGFR-mutated lung cancer: a review of the existing and emerging clinical data CS Lee, M Milone, N Seetharamu OncoTargets and therapy, 4579-4597, 2021 | 23 | 2021 |
| A comprehensive review of contemporary literature for epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer and their toxicity CS Lee, S Sharma, E Miao, C Mensah, K Sullivan, N Seetharamu Lung Cancer: Targets and Therapy, 73-103, 2020 | 15 | 2020 |
| Lorlatinib induced proteinuria: a case report CS Lee, R Wanchoo, N Seetharamu Journal of Oncology Pharmacy Practice 27 (4), 1037-1039, 2021 | 8 | 2021 |
| Primary-to-secondary care referral experience of suspected colorectal malignancy in young adults K Patel, T Doulias, T Hoad, C Lee, JC Alberts The Annals of The Royal College of Surgeons of England 98 (5), 308-313, 2016 | 8 | 2016 |
| A deep dive into CDK4/6 inhibitors: Evaluating real world toxicities and treatment paradigms in the elderly population C Olazagasti, CS Lee, A Liu, D Stefanov, K Cheng Journal of oncology pharmacy practice 29 (1), 14-21, 2023 | 7 | 2023 |
| A real world analysis of first line treatment of advanced EGFR mutated non-small cell lung cancer: A multi-center, retrospective study CS Lee, I Ahmed, E Miao, S Chung, K Patel, N Kohn, N Seetharamu Journal of Oncology Pharmacy Practice 28 (5), 1140-1151, 2022 | 7 | 2022 |
| A narrative review of the management of BRAF non-V600E mutated metastatic non-small cell lung cancer I Abuali, CS Lee, N Seetharamu Precis Cancer Med 5, 13, 2022 | 6 | 2022 |
| Amifostine is a nephro-protectant in patients receiving treatment with cisplatin-myth, mystery or matter-of-fact? SS Ha, K Rubaina, CS Lee, V John, N Seetharamu Journal of Nephrology and Dialysis Medicine 3 (1), 2021 | 6 | 2021 |
| Updated treatment options in the management of hyperkalemia KE Ng, C Lee US Pharm 42 (2), 2017 | 4 | 2017 |
| Epidemiology and clinicopathological features of lung cancer in patients with prior history of breast cancer KY Wang, J Newman, CS Lee, N Seetharamu SAGE Open Medicine 9, 20503121211017757, 2021 | 3 | 2021 |
| Impact of tyrosine kinase inhibitor starting dose on outcomes in patients with non-small cell lung cancer E Miao, N Seetharamu, K Sullivan, S Eng, CS Lee Journal of Pharmacy Practice 34 (1), 11-16, 2021 | 3 | 2021 |
| Inpatient utilization of immune checkpoint inhibitors and clinical outcomes J Wang, CS Lee, S Attarian, N Kohn, C Devoe Journal of Oncology Pharmacy Practice 29 (6), 1392-1397, 2023 | 2 | 2023 |
| Alectinib-induced hemolytic anemia CS Lee, K Sullivan Journal of Oncology Pharmacy Practice, 10781552221147840, 2023 | 2 | 2023 |
| A contemporary review of rearranged during transfection-selective inhibitors AW Liu, C Liang, CS Lee Journal of Oncology Pharmacy Practice 28 (1), 175-184, 2022 | 2 | 2022 |
| Back to the well: can patients with advanced non-small cell lung cancer benefit from changing PD-1/PD-L1 inhibitors after progression? J Newman, CS Lee, K McGovern, N Seetharamu Journal of Clinical Oncology 39 (15_suppl), e21194-e21194, 2021 | 2 | 2021 |
| A retrospective analysis of tumor lysis syndrome management in a quaternary care hospital S Eng, CS Lee, S Ahn, A Sharma Journal of Oncology Pharmacy Practice 26 (2), 338-344, 2020 | 2 | 2020 |
| A real world perspective of PARP inhibitor use in gynecological cancer patients CS Lee, J Hernandez, C Liang, A Leung, DG Stefanov, K Cheng, V John Journal of Pharmacy Practice 36 (5), 1134-1141, 2023 | 1 | 2023 |
